Integra LifeSciences Holdings Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Stuart Essig
- Full Time Employees
- 4,427
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1100 Campus Road Princeton NJ United States of America 08540
- IPO Date
- Aug 16, 1995
- CIK
- 0000917520
- Website
- integralife.com
- Similar Companies
- Business
- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global medical technology company founded in 1989 and headquartered in Princeton, New Jersey, develops, manufactures and markets surgical implants, instruments and regenerative technologies for neurosurgery, neurocritical care, extremity reconstruction, otolaryngology, wound care and general surgery; operates in two segments, Codman Specialty Surgical and Tissue Technologies; offers neurosurgery products including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, cranial stabilization equipment, surgical headlamps and instrumentation; provides over 40,000 instrument patterns, surgical and lighting products for hospitals, surgery centers, dental, podiatry and veterinary offices; supplies regenerative products for acute and chronic wounds such as burns and diabetic foot ulcers, along with surgical tissue repair solutions for hernia, tendon, peripheral nerve repair and protection, skin and bone grafts; delivers ear, nose and throat solutions encompassing instrumentation, balloon technologies for sinus and eustachian tube dilation, surgical navigation systems and the MicroFrance line; and sells directly through sales forces and distribution channels to hospitals, integrated health networks, group purchasing organizations and clinicians in the United States, Europe, Asia Pacific and internationally. The company recently completed its acquisition of Acclarent, Inc. from Johnson & Johnson MedTech in 2024 for $275 million plus up to $5 million in regulatory milestones, enhancing its ear, nose and throat portfolio with leading balloon sinuplasty and eustachian tube dilation technologies integrated into the Codman Specialty Surgical division; integrated the 2022 Surgical Innovation Associates acquisition, adding the DuraSorb resorbable synthetic matrix for plastic and reconstructive surgery including implant-based breast reconstruction; and continues to report organic revenue growth, with 7.1% in Q3 2025 amid focus on neurosurgical, ENT and regenerative product expansions.
Company News
Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting
INTEGRA LIFESCIENCES HOLDINGS CORPORATION IART INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 21.2% Share Drop
Integra LifeSciences (NASDAQ:IART) & Precision Optics (NASDAQ:POCI) Critical Review
Integra LifeSciences (NASDAQ: IART) prices $450 million notes to refinance debt
A Look at Integra Lifesciences Holdings Corp (IART) After 3.1% Gain -- GF Value $20.47 vs Price $13.41
INTEGRA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corporation on Behalf of Integra Stockholders and Encourages Investors to Contact the Firm
Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026
INTEGRA LIFESCIENCES HOLDINGS CORPORATION INVESTIGATION: IART Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for Direction
Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for Direction
Integra LifeSciences (NASDAQ: IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline
Integra LifeSciences (IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline
Integra LifeSciences (NASDAQ:IART) Announces FY 2026 Earnings Guidance
Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)
Integra LifeSciences lowers revenue and earnings outlook for 2026
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
IART vs. PEN: Which Stock Is the Better Value Option?
Should You Continue to Hold IART Stock in Your Portfolio?